ALPHAMAB-B(09966): The results of the KN026 adjuvant therapy for stage III breast cancer have been selected for presentation at the 2026 ASCO Annual Meeting as a Late-Breaking Abstract oral presentation.

ALPHAMAB-B (09966) announced that the significant results of the Phase III clinical study (study number: KN026-004) of the combination injection of docetaxel (albumin-bound) (HB1801) developed in collaboration with Shanghai Jinmant BioTech Co., Ltd., a subsidiary of CSPC PHARMA (01093), for adjuvant therapy of human epidermal growth factor receptor 2 (HER2) positive (HER2-positive) breast cancer (BC) have been selected for presentation at the Late-Breaking Abstract (LBA) oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is led by Professor Zhi-Min Shao from Fudan University Shanghai Cancer Center, marking a significant milestone for Chinese original innovative therapies on the international academic stage. KN026-004 is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of KN026 in combination with HB1801 carboplatin compared to trastuzumab in combination with pertuzumab and docetaxel carboplatin in the neoadjuvant treatment of early and locally advanced HER2-positive BC. The study results show that compared to the current standard treatment regimen (TCbHP), the KN026 combination therapy significantly improves the overall pathologic complete response (pCR) rate of patients. The study results demonstrate for the first time in a head-to-head Phase III clinical trial that the performance of the HER2 bispecific antibody is superior to the combination therapy of trastuzumab and pertuzumab with a better safety profile. The KN026 combination therapy is expected to become a new standard of care for neoadjuvant treatment of early and locally advanced HER2-positive BC.